MELISA STEELE: Open Payments
NPI 1003923988 · MURRAY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,113 in 90 payments from 13 companies in 2025. Trend: 2023 $1,307 · 2024 $1,282 · 2025 $2,113
Food & beverage: $2,071Education: $42
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 24 | $441 |
| AstraZeneca Pharmaceuticals LP | 15 | $430 |
| Novartis Pharmaceuticals Corporation | 16 | $270 |
| GlaxoSmithKline, LLC. | 11 | $241 |
| Regeneron Healthcare Solutions, Inc. | 8 | $139 |
| Organon LLC | 1 | $125 |
| Grifols USA, LLC | 4 | $119 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $97 |
| Regeneron Pharmaceuticals, Inc. | 1 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
Products named: DUPIXENT, NUCALA, AIRSUPRA, VTAMA, FASENRA, Prolastin-C Liquid, TEZSPIRE, Rhapsido.
Industry payments across UT — which companies pay providers there.
